Pros and cons in endocrine practice: pre-surgical treatment with somatostatin analogues in acromegaly

Marco Losa, Jens Bollerslev

Research output: Contribution to journalArticlepeer-review


The aim of this commentary is to balance the pros and cons for pre-surgical SSA treatment in a modern perspective ending up with a pragmatic recommendation for treatment based on the current evidence and expertise of the authors. Even though prospective and randomized studies in this particular area are hampered by obvious limitations, the interpretation of the four published trials has in general been in favor of pre-treatment with SSA, showing a better outcome following surgery. However, major drawbacks of these studies, such as non-optimal diagnostic criteria for cure, potential selection bias, and timing of the postoperative evaluation in SSA pre-treated patients, limit their overall interpretation. Three matched-controlled studies showed remarkably similar results with no apparent beneficial effect of SSA pre-treatment on surgical outcome. Both prospective, randomized studies and retrospective studies did not find any significant difference in the rate of endocrine and non-endocrine complications related to surgery, despite the beneficial clinical effects of SSA treatment in most acromegalic patients. The newly diagnosed patient with acromegaly should be carefully evaluated in the trans-disciplinary neuroendocrine team and treatment individualized accordingly. The issue of SSA pre-treatment to improve surgical outcome is yet to be settled and further methodologically sound studies are probably necessary to clarify this point.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
Publication statusAccepted/In press - Jan 19 2016


  • Acromegaly
  • Pituitary neoplasms
  • Pituitary surgery
  • Somatostatin analogues

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Pros and cons in endocrine practice: pre-surgical treatment with somatostatin analogues in acromegaly'. Together they form a unique fingerprint.

Cite this